Mednet Logo
SpecialtiesGynecologic Oncology
Gynecologic Oncology

Gynecologic Oncology

Clinical discussions on gynecologic malignancies, surgical approaches, and multimodal treatment strategies.

Recent Discussions

Is peritoneal dialysis a contraindication to pelvic radiotherapy?

3
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I have never done it except for a few patients with palliation as treating the entire pelvis may increase the risk of complications of dialysis and also may decrease efficacy and with changes in peritoneal permeability unless treating localized field like prostate or below the peritoneal reflection....

What is your approach to adjuvant treatment for stage IA small cell carcinoma of the ovary, hypercalcemic type, after fertility sparing surgical staging?

2
1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Cincinnati Children's Hospital Medical Center

Due to the rarity of small cell carcinoma of the ovary hypercalcemic type (SCCOHT), limited prospective data exists to inform treatment decisions. Like other malignancies in the malignant rhabdoid tumor (MRT) family including renal and extra-renal MRT and atypical teratoid rhabdoid tumors (ATRT), SC...

Does the presence of an ATM mutation in advanced stage ovarian cancer influence the decision to use Bev vs PARP inhibitor for maintenance?

2 Answers

Mednet Member
Mednet Member
Gynecologic Oncology · UCSD Moores Cancer Center

I would not use the presence of an ATM mutation alone to inform decisions between bevacizumab vs PARPi maintenance. There are several options for maintenance in the 1L setting, and these include single agent PARPi, PARPi + bevacizumab, or bevacizumab monotherapy. Using data from the PAOLA-1 trial, i...

How would you manage a large grade 2 endometrial adenocarcinoma with invasion into the parametria and upper vagina without nodal or metastatic disease?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

PETCT and MRI. Preoperative chemo RT with EBRT plus brachy followed by surgery. Vargo et al., PMID 25218303

When a patient with a preexisting rheumatic disease and on immunotherapy begins to flare, how do you decide if this is an underlying rheumatic disease activity versus an immunotherapy related adverse event?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · Johns Hopkins School of Medicine

If the symptoms/signs are similar to their prior flares of their rheumatic disease, then it is likely a flare. Over 50% of patients with autoimmune diseases flare on immune checkpoint inhibitor therapy if you look at systematic literature reviews of the limited published data. If symptoms are unrela...

Would you consider definitive radiation therapy (EBRT + interstitial HDR) in lieu of pelvic exenteration for a vaginal spindle cell sarcoma?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I would not favor definitive RT unless not a surgical candidate but sometimes have been able to do EBRT plus brachy after gross total excision to avoid exenteration.

Would you consider adding adjuvant vaginal cuff brachytherapy for a FIGO 1A endometrial cancer, G1, no LVSI, based on the presence of extensive lower uterine segment involvement?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

It’s not an absolute indication for adjuvant brachy with small absolute benefit.

How would you manage a dehiscent vaginal cuff 2 months after vaginal cuff brachytherapy?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

It has to be a combination of surgery and radiation. Partial small dehiscence can sometimes be managed conservatively otherwise, most need surgical fixation.

How would you treat a recurrent ovarian malignant mixed Mullerian tumor on the pelvic side wall?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I would treat with IMRT and IGRT with total dose equivalent to 66 Gy based on OAR dosimetry to buy time without chemo and improve PFS.

What features help distinguish thyroid myopathy from immune checkpoint inhibitor-associated myopathy?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · Yale School of Medicine

Immune checkpoint inhibitors (ICIs) can cause myositis (ICI-myositis). Since ICIs can also induce hypothyroidism, myopathy secondary from hypothyroidism can also be associated with ICI therapy. Different from thyroid myopathy, patients with ICI-myositis barely have myoedema or muscle pseudohypertrop...